Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Irisity in connection with new issues
Mandate

Vinge advises Irisity in connection with new issues

November 07, 2017 Capital Markets and Public M&A

Vinge is advising Irisity AB (publ), listed on Nasdaq First North, in connection with a rights issue and a directed new issue of shares.

The rights issue is underwritten to 100% through subscription undertakings and underwriting guarantees. The directed issue occurs via Vätterledens Invest and Hans Andersson & Co AB, both long term strategic investors. An extraordinary general meeting will adopt a resolution concerning the issues on 24 November and a prospectus is expected to be published on 5 December with the subscription period commencing on 7 December. Irisity conducts operations within intelligent camera surveillance and develops camera solutions with the help of proactive working and self learning algorithms.

Vinge’s team consists of Anders Strid, Frida Bäckegren, Joel Zetterström (IP) and corporate assistant Camilla Andersson.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025